, Tracking Stock Market Picks
Enter Symbol:
Insmed, Inc. (INSM) [hlAlert]

up 675.61 %

Insmed, Inc. (INSM) rated Buy by ThinkEquity

Posted on: Thursday,  Aug 16, 2012  8:25 AM ET by ThinkEquity

ThinkEquity rated Buy Insmed, Inc. (NASDAQ: INSM) on 08/16/2012, when the stock price was $3.24. Since
then, Insmed, Inc. has gained 675.62% as of 01/15/2016's recent price of $25.13.
If you would have followed this ThinkEquity's recommendation on INSM, you would have gained 675.61% of your investment in 1247 days.

Insmed Incorporated (Insmed) is a development stage biopharmaceutical company specializing in recombinant protein drug development. The Company also engaged the services of RBC to act as financial advisor. On March 31, 2009, the Company completed the sale of its follow-on biologics assets to Merck & Co., Inc. (Merck).

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/16/2012 8:25 AM Buy
as of 12/31/2012
1 Week up  3.72 %
1 Month down  -6.56 %
3 Months up  47.03 %
1 YTD up  106.48 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy